NASDAQ:DNTH • US2528281080
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for DIANTHUS THERAPEUTICS INC (DNTH).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-09 | Wolfe Research | Initiate | Outperform |
| 2026-03-19 | Wells Fargo | Initiate | Overweight |
| 2026-03-12 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-03-10 | Clear Street | Maintains | Buy -> Buy |
| 2026-03-10 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-03-10 | Raymond James | Upgrade | Outperform -> Strong Buy |
| 2026-03-10 | Baird | Maintains | Outperform -> Outperform |
| 2026-03-09 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2026-03-09 | Truist Securities | Maintains | Buy -> Buy |
| 2026-03-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-03-04 | Guggenheim | Maintains | Buy -> Buy |
| 2026-02-11 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-02-02 | Jefferies | Maintains | Buy -> Buy |
| 2026-01-08 | Truist Securities | Maintains | Buy -> Buy |
| 2025-12-22 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-11-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-06 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-10-14 | Truist Securities | Initiate | Buy |
| 2025-09-17 | Clear Street | Initiate | Buy |
| 2025-09-12 | Stifel | Maintains | Buy -> Buy |
| 2025-09-12 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-09-09 | Guggenheim | Maintains | Buy -> Buy |
| 2025-09-09 | Raymond James | Reiterate | Outperform -> Outperform |
| 2025-09-09 | Baird | Maintains | Outperform -> Outperform |
| 2025-09-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.826M | 6.235M 120.63% | 2.036M -67.35% | 1.299M -36.20% | 1.682M 29.48% | 15.606M 827.82% | 198.45M 1,171.63% | 680.47M 242.89% | 1.202B 76.64% | 1.674B 39.27% | 2.065B 23.36% | |
| EBITDA YoY % growth | -48.107M 39.08% | -101.768M -111.55% | -177.822M -74.73% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -48.174M 40.45% | -101.864M -111.45% | -177.933M -74.68% | -228.854M -28.62% | -268.547M -17.34% | -308.67M -14.94% | -202.539M 34.38% | 177.66M 187.72% | 580.21M 226.58% | 938.65M 61.78% | 1.247B 32.85% | |
| Operating Margin | -1,704.67% | -1,633.74% | -8,739.34% | -17,617.74% | -15,965.94% | -1,977.89% | -102.06% | 26.11% | 48.27% | 56.07% | 60.39% | |
| EPS YoY % growth | -12.97 37.16% | -2.60 79.95% | -4.10 -57.69% | -4.52 -10.23% | -5.07 -12.25% | -5.58 -10.03% | -4.98 10.72% | 0.06 101.18% | 6.17 10,421.74% | 11.29 82.98% | 15.70 39.08% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.08 -32.30% | -1.10 -25.02% | -1.14 -17.62% | -1.25 12.57% | -1.10 -1.54% | -1.11 -0.83% | -1.09 4.79% | -1.41 -13.00% |
| Revenue Q2Q % growth | 369.454K -68.23% | 308.55K 59.87% | 311.824K -21.26% | 357.071K 25.73% | -100.00% | -100.00% | -100.00% | -100.00% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -51.142M -54.15% | -53.176M -52.25% | -55.821M -38.56% | -63.023M 9.37% | -54.807M -7.17% | -55.452M -4.28% | -54.006M 3.25% | -73.757M -17.03% |
All data in USD
22 analysts have analysed DNTH and the average price target is 128.3 USD. This implies a price increase of 46.13% is expected in the next year compared to the current price of 87.8.
DIANTHUS THERAPEUTICS INC (DNTH) will report earnings on 2026-05-07.
The consensus EPS estimate for the next earnings of DIANTHUS THERAPEUTICS INC (DNTH) is -1.08 USD and the consensus revenue estimate is 369.45K USD.
The consensus rating for DIANTHUS THERAPEUTICS INC (DNTH) is 88.1818 / 100 . This indicates that analysts generally have a positive outlook on the stock.